This reciprocal cross-talk between the PI3K/AKT and AR pathways suggests that the combined inhibition of the AR and PI3K/AKT pathways may be necessary to achieve more complete tumor control and improve efficacy. The gene discussed is AKT1; the disease is neoplasm.